Bryant D. Lim joined Prelude Therapeutics in 2023 as Chief Legal Officer and Corporate Secretary. He was named Interim Chief Financial Officer in April 2024. He has more than 20 years of experience in pharma and biotech, with expertise in business development, regulatory matters, fundraising and SEC reporting. Prior to joining Prelude, Mr. Lim was Chief Business Officer and General Counsel at Aceragen, Inc. (previously Idera Pharmaceuticals). Previous to that, he served as Vice President of Legal at Incyte Corporation, having previously served as the Global Chief Compliance Officer. Earlier in his career, he was associate general counsel at ViroPharma Incorporated (until its acquisition by Shire Pharmaceuticals) and assistant counsel at Merck & Co., Inc. He currently serves on the Board of Directors of Life Sciences of Pennsylvania. Mr. Lim earned his law degree from Villanova University School of Law.